Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO

Launched by IRCCS SAN RAFFAELE · Jan 21, 2025

Keywords

ClinConnect Summary

The SURVIVE trial is studying a medication called cangrelor to see if it can help patients who are experiencing serious heart issues, specifically cardiogenic shock or cardiac arrest, while they are on a life-support treatment called VA-ECMO. The goal is to find out if cangrelor can reduce bleeding risks while still effectively preventing blood clots during a procedure to open blocked heart arteries. Participants will receive cangrelor along with another medication to thin their blood, and their platelet function (which helps the blood to clot) will be monitored closely throughout the treatment. After the VA-ECMO support ends, patients will switch to oral medications to continue managing their blood clotting.

To be eligible for this trial, participants must be adults aged 18 or older who are experiencing heart issues that require VA-ECMO and a procedure to open blocked arteries. They should have either received a specific dose of aspirin before the trial or have never taken blood-thinning medications. However, individuals with severe bleeding problems, a history of certain strokes, or those who are pregnant cannot participate. If you join the trial, you’ll receive careful monitoring and support to help ensure your safety and health during the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female patients aged ≥18 years;
• • ACS-related CS/CA patients undergoing PCI (either with or without stent implantation) and needing VA-ECMO support;
• • Patients who received pre-hospital aspirin intravenous loading dose or patients naïve to any anti-thrombotic agent;
• • Written informed consent
• Exclusion Criteria:
• • Overt uncontrollable bleeding;
• • Suspected intra-cranial haemorrhage;
• • Patients who received any dose of any oral P2Y12-inhibitors;
• • Patients with known history of stroke or Transient Ischaemic Attack (TIA);
• • Patients with known hypersensitivity to the active substance (cangrelor) or to any of its excipients;
• • Pregnancy.